
Bahija Jallal, Immunocore CEO
FDA hurries up a quick approval for the world's first TCR — after a 14-year R&D trek
Over the 14 years since Immunocore was spun out of MediGene in a quest to develop a gamechanging cancer med, the biotech has raised record sums and undergone a major shakeup on a long roller coaster ride of valuations for investors. But they survived and thrived and today they’re popping the champagne corks to celebrate an FDA approval of their first TCR drug.
Immunocore flagged the FDA’s green light for tebentafusp Wednesday morning by highlighting a series of firsts.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters